2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Adverse Events, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Quality of Care, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Translational Research, Clinical Research, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult, Young Adult
PAPER

3294 Impact of timing of MRD negativity on survival outcomes in adults with ph+ ALL treated with blinatumomab and ponatinib

Amin Azem, MD, Danny Walgenbach, MD2, Abigail Huetteman, MD3, Katherine Tobon, PharmD4, Ziad Abuhelwa, MD, MPH5, Ghada Araji, MD6, Kriti Gera, MD7, Leidy Isenalumhe, MD, MS8, Jennifer Eatrides, MD9, Julio C Chavez, MD, MS10, Bijal Shah, MD, MS11
1 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
2 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
3 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
4 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
5 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
6 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
7 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
8 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
9 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
10 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
11 H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Background:

Ponatinib plus blinatumomab is a standard treatment for Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Measurable residual disease (MRD), assessed using increasingly sensitive methods, is an important prognostic marker for relapse and guides treatment decisions. At our institution, adults with Ph+ ALL receive a TKI-based induction regimen, often combined with dose-adjusted chemotherapy, followed by up to five or six cycles of blinatumomab plus ponatinib.

Primary Objective:

To assess whether the timing of achieving MRD negativity affects survival outcomes in adults with Ph+ ALL treated with blinatumomab and ponatinib.

Methods:

We conducted a retrospective, observational, single-center review of adult (≥18 years) patients with Ph+ ALL treated with a TKI-based chemotherapy induction followed by blinatumomab and ponatinib at Moffitt Cancer Center between January 1, 2017 and October 1, 2025, in the first- or second-line setting, who had trackable MRD by next generation sequencing (NGS). Patient characteristics and MRD time points were captured through retrospective chart review across therapy phases. Overall survival (OS), and event-free survival (EFS) were estimated by the Kaplan-Meier method and measured from the date of induction. OS was defined as the time to death from any cause. EFS was defined as death from any cause, disease relapse at any site, or rising MRD by NGS requiring a change in therapy, whichever came first. MRD negativity was defined as an undetectable clone or a level below NGS level of detection. Early MRD negativity was defined as MRD negativity after completion of induction and before the first cycle of blinatumomab; late MRD negativity as MRD negativity achieved at any point during blinatumomab and ponatinib therapy.

Results:

Forty-one patients met eligibility criteria; 11 (27%) achieved early MRD negativity and 30 (73%) achieved late MRD negativity. Median age at diagnosis was 54 years (range, 19–77); 22 (54%) were male. Median WBC at diagnosis was 20.6 × 10⁹/L (range, 2.9–336.3), and median LDH relative to the upper limit of normal was 2.09 (range, 0.90–13.6). Thirty-two (78%) had the p190 BCR::ABL1 transcript, 8 (20%) had prior TKI exposure, 2 (5%) had prior CNS involvement, and 12 (24%) had IKZF1 alterations. Two (5%) had CML in blast phase. Thirty-four (83%) were treated in the first-line setting, and 24 (59%) received attenuated induction chemotherapy before blinatumomab and ponatinib. The median number of blinatumomab cycles was 4 (range, 1–6); 10 (24%) underwent allogeneic stem-cell transplantation (ASCT) and 1 (2%) received CAR T-cell therapy.

At a median follow-up of 39.0 months (range, 7.1–66.6), 48-month OS was 100% in the early MRD-negative group versus 88.5% (95% CI, 68.3–96.2) in the late group (P=0.24). The 48-month EFS was 87.5% (95% CI, 38.7–98.1) versus 78.7% (95% CI, 54.5–91.0), respectively (P=0.6). Median OS and EFS were not reached in either group.

The early MRD group had a single event: rising MRD attributed to non-adherence with maintenance TKI therapy. In the late MRD group, 2 events were deaths without documented relapse (one from sepsis in the immediate post-transplant period, one from pneumonia 12 months after completing therapy), and 3 were relapses—marrow relapse at 1 year in a patient with high-risk disease at diagnosis (high WBC, IKZF1); combined marrow and nodal relapse; and CSF relapse in a patient with lymphoid blast-phase CML.

Conclusion:

These results suggest that early MRD negativity may be associated with superior survival outcomes. Although neither comparison reached statistical significance, the analysis is likely underpowered by sample size. The numerical difference may have been more pronounced had the single early-group event not been driven by non-adherence. These findings also raise the question of whether alternative novel therapies, such as CAR T-cell therapy, should be considered when MRD persists during first remission despite chemotherapy-based induction therapy in patients with Ph+ ALL. Ongoing early-phase clinical trials, including NCT06144606 and NCT07053059, may help clarify the optimal treatment strategy in this setting.

Amin Azem, MD: No relevant conflicts of interest to declare.